Solid biosciences announces updated corporate strategy to develop sgt-001 and sgt-003 pipeline programs for patients with duchenne muscular dystrophy

- ignite dmd functional and durability patient data support advancement of sgt-001; program transitioning to a commercially scaled transient transfection-based manufacturing process -

SLDB Ratings Summary

SLDB Quant Ranking